Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
On Tuesday, April 8, 2025, in New York, USA, USA, New York, USA, New York, USA, New York, USA, New York, New York, New York, USA.
Michael Nagl | Bloomberg | Gets the image
Measure On Tuesday, they said that by the end of 2027 it would reduce $ 3 billion to be fully reinvested to support new products and its addiction.
Perennial efforts come when Merck is preparing to compensate for profits from future patent drug paten Planned tariffs for pharmaceuticals imported in the USA, that pushed Merck and other companies invest billions to increase their production marks in the US
“Today, we have announced a long-standing optimization initiative, which redirects investments and resources from more permanent areas of our business into our growth of new growth drivers, which will further transform our portfolio and lead to the next chapter of productive growth,” said Merck Rob Davis.
As part of the efforts, Merc approved a new restructuring program that eliminates certain administrative, trade and research and development. But the company will continue to hire employees in new roles in its business. Merck also reduce its global real estate trace and continues to return its production network.
Merck expects the actions under the restructuring program will receive about $ 1.7 billion in annual cost savings, most of which will begin by the end of 2027.
The company expects that Profax costs related to the restructuring program amounted to approximately $ 3 billion. In the second quarter, Merck recorded a $ 649 million fee related to the program.
Also on Tuesday, Merck announced the profit in the second quarter, which was assessed by Wall Street. It was the first time the metric had missed expectations since April 2021.
While Keytruda’s sales grew during this period, Merc continued to see problems with Gardassil sales in China, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection
In February, Merc announced the decision to stop the supplies of Gardosil to China, starting this month and passed at least in mid -2015. In the prepared statements on Tuesday, the Merck Caroline Litchfield CEO stated that the company did not restore supplies to China until at least the end of 2025, noting that the reserves remain high and demand is still soft.
The company also narrowed its full years. Now Merck expects its adjusted profit from 2025 to be from $ 8.87 to $ 8.97 per share. This is compared to the previous forecast from $ 8.82 to $ 8.97 per share.
Merck expects that the profit per year will be from $ 64.3 billion to $ 65.3 billion, narrowing at both ends from the previous $ 64.1 to $ 65.6 billion.
That’s what Merck reported for the second quarter compared to what Wall -Rate was waiting for LSEG analyst survey:
- Profit per share: $ 2.13 is adjusted. This figure may not be comparable to $ 2.01 estimates.
- Income: 15.81 billion dollars against $ 15.89 billion expected
Merc noted that his leadership includes previously announced $ 200 million related to tariffs that Trump has sold today. In April, the company said The expected tariff charge First of all, it reflects the levies between the US and China, but does not take into account the spheres of pharmaceutical tariffs.
The forecast also includes disposable fees related to the company’s licensed agreements with Hengrui Pharma and Lanova, but not recently announced acquisition of Verona Pharma.
The company offered a net profit of $ 4.43 billion, or $ 1.76 per quarter. This is compared to a net profit of $ 5.46 billion, or $ 2.14 per share, for a year and affiliation.
With the exception of the cost of purchasing and restructuring, Merck earned $ 2.13 per share for the second quarter. This includes a fee for 7 cents for the action for closing the license agreement with the Hengrui Pharma.
Merck took $ 15.81 billion of the quarter profit, which is 2% compared to the same period a year ago.
Pharmaceutical, animal health sales
The Merck Pharmaceutical Block, which develops a wide range of drugs, has booked $ 14.05 billion in the second quarter. This decreased by 2% compared to the same period earlier.
Keytruda has recorded 7.96 billion revenue per quarter, which is 9% compared to the period and belonging.
Such an increase was due to the higher Keytruda absorption for cancer stage and strong demand for the drug for metastatic cancers spread to other parts of the body, the company notes. Strateaccount estimates that analysts expected drugs to see $ 7.9 billion.
Gardosil brought sales of $ 1.13 billion per quarter, which is 55% compared to the same period a year ago due to a decrease in demand in China. Analysts expected Gardosil to order a $ 1.33 billion sales, Stretaccont estimates.
The Chinese market is the majority of international blockbuster’s revenues. Merc hopes that the extended statement of Gardosil for men between the ages of 9 and 26 in China will help increase the absorption of the vaccine.
Gardosila sales in the United States increased by 2% in the second quarter.
Meanwhile, the new Merck Winrevair drug used to treat a rare, deadly lung condition, has recorded $ 336 million per quarter. Stretaccount estimates that analysts expected drugs to lead $ 324.7 million.
The Merck animal health department, which develops vaccines and medicines for dogs, cats and cattle, has placed almost $ 1.65 billion, which is 11% compared to the same period up to a year. The company said the higher demand for animals and sales from Aqua Business Elanco, which it acquired last year, went from this growth.
